NATCO Pharma LimitedNSE: NATCOPHARM

Press Release Dec 05 2022

· Issued by NATCO Pharma Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

NATCO Pharma Limited has issued a press release regarding a legal judgment. The Delhi High Court dismissed an appeal from FMC Corporation and upheld NATCO's position on its Chlorantraniliprole process. This ruling confirms that NATCO's process does not infringe FMC's patent.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

NATCO Pharma Limited on 6ix

Earlier from NATCO Pharma

Later from NATCO Pharma

All NATCO Pharma news releases